Medical Education:

Washington University School of Medicine (St. Louis) - 1966- 1971

Washington University Internal Medicine Internship - 1971-1972

Washington University Residency in Internal Medicine/ Psychiatry - 1972-1976

Washington University Residency in Internal Medicine/ Psychiatry - 1972-1976

Awards:

Phi Beta Kappa - University of Missouri

Markle student fellowship in Nephrology research - 1970-1971

Marquis Whos Who in Medicine and Healthcare (1st - 4th editions) - 1987- 2006

Marquis Whos Who of American Inventors of the 1990's - 1990

Marquis Whos Who in America (52- 58th editions) - 1998 - 2006

Marquis Whos Who in the World (15th edition 21st editions) 1998 - 2006

Marquis Whos Who in Science & Engineering (4th - 7th editions) - 1998-2006

Fellow, - American College of Forensic Examiners - 1998

Eight U.S. and international PATENTS in pharmacology of neurodegenerative illnesses

Appointments:

Assist Prof of Psychiatry & Internal Medicine - U. Pittsburgh - 1976- 1978

Assist Prof of Psychiatry & Internal Medicine - U. Southern California - 1978 - 1981

Assoc Prof of Research in Psychiatry - U. of California, Los Angeles - 1981- 1988

Medical Director- Solo Not for Profit Research Foundation - 1992 - present

President & CEO - Alzheimers Corporation, Albuquerque, NM - 1999 - present

WALL STREET JOURNAL ARTICLES
CITING DR. SUMMERS WORK or BY DR. SUMMERS

1. Waldholtz, Michael. "A Psychiatrists Work Leads to a U.S. Study of Alzheimers Drug. But Dr. Summers Shuns test, seeks to widen his own; Is memory really aided? The Fee-for- Research Furor." Wall Street Journal. Tuesday August 4, 1987, page A-1.

2. Editorial Staff. "Questions about Alzheimers." Wall Street Journal. Thursday, August 6,1987. Editorial page.

3. Editorial Staff. "Policing Alzheimers" Wall Street Journal. Thursday, March 3, 1988. Editorial page.

4. Editorial Staff. "Support for Dr. Summers." Wall Street Journal. Tuesday, March 22, 1988. Editorial page.

5. Waldholtz, M. "Physician to Defy FDA, Take Money from Test Patients." Wall Street Journal. Monday, March 28, 1988.

6. Summers, WK. "Alzheimers Quagmire." Wall Street Journal. Monday, April 4, 1988. Letters to the editor.

7. Sattin, Albert. "THA Takes on Alzheimers and FDA." Wall Street Journal. Monday, April 11, 1988. Editorial section.

8. Editorial Staff. "Wichita Falls Call the FDA." Wall Street Journal. Friday, April 29, 1988. Editorial page.

9. Editorial Staff. "The Sunday Times: new drug helps Nobel winner regain his memory." Wall Street Journal. Wednesday, December 7, 1988. Editorial page.

10. Editorial Staff. "Punishing Alzheimers Patients." Wall Street Journal. Tuesday, February 14, 1989. Editorial page.

11. De Lisser, Eleena. "Can you prevent Alzheimers disease?" Wall Street Journal. Thursday, May 16, 2002 page D1.

12. Summers WK. "FDA should be confined to its original mission." Wall Street Journal. Tuesday, April 1, 2003, editorial page.

Major Research Publications (43 citations):

Summers WK, Jamison RL. The no reflow phenomenon in renal ischemia. Laboratory Investigation 1971;
25: 635-43.

Summers WK, Allen RE, Pitts RN. Drug modification of electroconvulsive therapy: methohexital and
diazepam III. Biological Psychiatry 1980; 15:257-64.

Summers WK, Majovski LJ, Marsh GM, Tachiki KH, Kling A. Use of oral THA in long-term treatment of
senile dementia, Alzheimer's type. New England Journal of Medicine 1986; 315:1241-1245.

Summers, WK. Alzheimer's drug needs individually set dose. The Wall Street Journal. Wed.,
December 8, 1993, page A15.

Summers, WK. "Tacrine (THA, Cognex)" Journal of Alzheimers Disease. 2: 85-93, 2000.

Summers, WK. Alzheimers disease, oxidative injury, and cytokines. Journal of Alzheimers Disease. 6:651-657, 2004.

(more) available upon request